Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus
Abstract Hepatitis E virus (HEV) infection is a major cause of acute viral hepatitis worldwide. The efficacy and safety of the HEV239 vaccine have been validated, with protection lasting at least 10 years. This study extended the phase 3 trial of HEV239 (NCT01014845), presenting data on the durabili...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-024-01041-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846112889083002880 |
|---|---|
| author | Kongxin Zhu Mengjun Liao Lu Chen Jiaoxi Lu Xingcheng Huang Chunlan Zhuang Yingying Su Shoujie Huang Ting Wu Jun Zhang Ningshao Xia |
| author_facet | Kongxin Zhu Mengjun Liao Lu Chen Jiaoxi Lu Xingcheng Huang Chunlan Zhuang Yingying Su Shoujie Huang Ting Wu Jun Zhang Ningshao Xia |
| author_sort | Kongxin Zhu |
| collection | DOAJ |
| description | Abstract Hepatitis E virus (HEV) infection is a major cause of acute viral hepatitis worldwide. The efficacy and safety of the HEV239 vaccine have been validated, with protection lasting at least 10 years. This study extended the phase 3 trial of HEV239 (NCT01014845), presenting data on the durability of the anti-HEV IgG response elicited by one or two doses in the participants with different baseline serostatus. Over half of baseline seronegative individuals retained detectable antibodies at month 91 after two doses, with geometric mean concentration levels above the detection limit at month 67 (no available data for month 91). Seropositive individuals exhibited more prolonged and higher anti-HEV IgG response. After a single dose, individuals with pre-existing immunity achieved high and sustained antibody levels for over 103 months, comparable to the two-dose regimen. Both single-dose and two-dose HEV239 regimens demonstrated notable immunogenicity and persistence, potentially offering substantial protective benefits. |
| format | Article |
| id | doaj-art-ee3aec2f49f247eaa419188239b97b2f |
| institution | Kabale University |
| issn | 2059-0105 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-ee3aec2f49f247eaa419188239b97b2f2024-12-22T12:13:12ZengNature Portfolionpj Vaccines2059-01052024-12-01911610.1038/s41541-024-01041-5Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatusKongxin Zhu0Mengjun Liao1Lu Chen2Jiaoxi Lu3Xingcheng Huang4Chunlan Zhuang5Yingying Su6Shoujie Huang7Ting Wu8Jun Zhang9Ningshao Xia10State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen UniversityState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen UniversityState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen UniversityState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen UniversityState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen UniversityState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen UniversityState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen UniversityState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen UniversityState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen UniversityState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen UniversityState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen UniversityAbstract Hepatitis E virus (HEV) infection is a major cause of acute viral hepatitis worldwide. The efficacy and safety of the HEV239 vaccine have been validated, with protection lasting at least 10 years. This study extended the phase 3 trial of HEV239 (NCT01014845), presenting data on the durability of the anti-HEV IgG response elicited by one or two doses in the participants with different baseline serostatus. Over half of baseline seronegative individuals retained detectable antibodies at month 91 after two doses, with geometric mean concentration levels above the detection limit at month 67 (no available data for month 91). Seropositive individuals exhibited more prolonged and higher anti-HEV IgG response. After a single dose, individuals with pre-existing immunity achieved high and sustained antibody levels for over 103 months, comparable to the two-dose regimen. Both single-dose and two-dose HEV239 regimens demonstrated notable immunogenicity and persistence, potentially offering substantial protective benefits.https://doi.org/10.1038/s41541-024-01041-5 |
| spellingShingle | Kongxin Zhu Mengjun Liao Lu Chen Jiaoxi Lu Xingcheng Huang Chunlan Zhuang Yingying Su Shoujie Huang Ting Wu Jun Zhang Ningshao Xia Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus npj Vaccines |
| title | Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus |
| title_full | Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus |
| title_fullStr | Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus |
| title_full_unstemmed | Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus |
| title_short | Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus |
| title_sort | persistence of hepatitis e vaccine induced antibody response across different dosage schedules and baseline serostatus |
| url | https://doi.org/10.1038/s41541-024-01041-5 |
| work_keys_str_mv | AT kongxinzhu persistenceofhepatitisevaccineinducedantibodyresponseacrossdifferentdosageschedulesandbaselineserostatus AT mengjunliao persistenceofhepatitisevaccineinducedantibodyresponseacrossdifferentdosageschedulesandbaselineserostatus AT luchen persistenceofhepatitisevaccineinducedantibodyresponseacrossdifferentdosageschedulesandbaselineserostatus AT jiaoxilu persistenceofhepatitisevaccineinducedantibodyresponseacrossdifferentdosageschedulesandbaselineserostatus AT xingchenghuang persistenceofhepatitisevaccineinducedantibodyresponseacrossdifferentdosageschedulesandbaselineserostatus AT chunlanzhuang persistenceofhepatitisevaccineinducedantibodyresponseacrossdifferentdosageschedulesandbaselineserostatus AT yingyingsu persistenceofhepatitisevaccineinducedantibodyresponseacrossdifferentdosageschedulesandbaselineserostatus AT shoujiehuang persistenceofhepatitisevaccineinducedantibodyresponseacrossdifferentdosageschedulesandbaselineserostatus AT tingwu persistenceofhepatitisevaccineinducedantibodyresponseacrossdifferentdosageschedulesandbaselineserostatus AT junzhang persistenceofhepatitisevaccineinducedantibodyresponseacrossdifferentdosageschedulesandbaselineserostatus AT ningshaoxia persistenceofhepatitisevaccineinducedantibodyresponseacrossdifferentdosageschedulesandbaselineserostatus |